6.2.4. investigational therapies. 6.2.4.1. background besides rp, ebrt bt, modalities emerged potential therapeutic options patients clinically localised pca [733-735]. new modalities developed minimally invasive procedures aim providing equivalent oncological safety, reduced toxicity, improved functional outcomes. section, whole gland- focal treatment considered, looking particularly high-intensity focused us (hifu), cryotherapeutic ablation prostate (cryotherapy) focal photodynamic therapy (pdt), sufficient data available form basis initial judgements. options radiofrequency ablation (rfa) electroporation, among others, considered early phases evaluation . 6.2.4.2. whole-gland therapies 6.2.4.2.1. cryotherapy whole-gland treatment cryotherapy uses freezing techniques induce cell death dehydration resulting protein denaturation, direct rupture cellular membranes ice crystals vascular stasis microthrombi, resulting stagnation microcirculation consecutive ischaemic apoptosis [733-735]. freezing prostate ensured placement 17-gauge cryo-needles trus guidance, placement thermosensors level external sphincter rectal wall, insertion urethral warmer. two freeze-thaw cycles used trus guidance resulting temperature -40°c mid-gland neurovascular bundle. currently, third fourth generation cryotherapy devices mainly used. since inception, cryotherapy used whole-gland treatment pca either primary salvage treatment option. main adverse effects whole-gland cryosurgery ed (18%), urinary incontinence (2–20%), urethral sloughing (0–38%), rectal pain bleeding (3%) recto-urethral fistula formation (0–6%) . lack prospective comparative data regarding oncological outcomes whole-gland cryosurgery curative treatment option men localised pca, studies non-comparative single-arm case series short follow-up . 6.2.4.2.2. high-intensity focused ultrasound whole-gland treatment high-intensity focused us consists focused us waves emitted transducer cause tissue damage mechanical thermal effects well cavitation . goal hifu heat malignant tissue 65°c, destroyed coagulative necrosis. high-intensity focused us performed general spinal anaesthesia, patient lying lateral supine position. since ultrasound energy often delivered rectal cavity, hifu faces challenges delivering energy anterior part large prostates. high-intensity focused us previously widely used whole-gland therapy following adverse effects: acute urinary retention (10%), ed (23%), urethral stricture (8%), rectal pain bleeding (11%), recto-urethral fistula (0–5%) urinary incontinence (10%) . combining whole-gland hifu treatment tur-p reduces rate urethral strictures, maintains level incontinence, increases rate ed . overall, lack long-term prospective comparative studies, data suggest poor long-term oncological outcomes men high-risk localised disease prevents whole-gland hifu considered reasonable alternative established curative treatment options . addition, expected improvements functional outcome failed materialise 12% patient developing incontinence 61% developing ed . 6.2.4.3. focal therapy past two decades, trend towards earlier diagnosis pca result greater public professional awareness leading adoption formal informal screening strategies. effect men identified earlier stage smaller tumours, greater propensity unifocal disease potentially suitable focal therapy [743-745]. also greater awareness risks consequences treatment leading attempts ablate region prostate containing tumour thereby limiting toxicity sparing neurovascular bundles, sphincter, urethra [746-748]. question remains small unifocal tumours need treatment. sr included data 5,827 patients across 72 studies covered different energy sources including hifu, cryotherapy, pdt, laser interstitial thermotherapy, focal bt, irreversible electroporation (ire) radiofrequency ablation (rfa) . review favours hifu pdt higher quality data, 95% pad-free incontinence 85–90% patients without clinically significant cancer short-term analysis. critically analysed, 45% patients focal approach included sr isup grade group 1 cancer. overall quality evidence low, due majority studies single-centre, non-comparative retrospective design, heterogeneity definitions approaches, follow-up strategies, outcomes, duration follow-up. although review finds high quality evidence focal therapy favourable functional outcomes minimises aes, definitive proof oncological effectiveness focal therapy compared standard treatments remains unavailable. currently largest analysis oncologic outcomes following focal hifu includes 625 patients, 70% isup grade group 2/3 disease, followed five years 88% failure-free survival (ffs), defined need salvage treatment systemic therapy . study one repeated focal hifu session allowed performed 25% patients. follow-up driven psa clinics, re-biopsies performed 36% patients significant psa rise suspicious mri. guideline panel acknowledges challenges interventional rcts [751-753]. interim analysis meeting reports demonstrate slow recruitment, patients declining consent rejecting treatment allocation rp group. attempt overcome propensity-matched analysis using prospective multi-centre databases performed comparison focal therapy vs. radical therapy . analyses always susceptible unmeasured selection biases selected treatment. oncological follow-up data 8 years used counsel patients treatment decisions . patients managed focal therapy hifu cryotherapy, one retreatment, needed. 17.1% patients focal arm received retreatment. primary outcome ffs defined “need local systemic salvage treatment metastasis”. groups included 246 patients average psa 7.9 ng/ml 60% isup grade group 2/3 cancers. cancer core length 5–6 mm 45% bilateral cancer. authors report similar cancer control 8 years therapy, ffs bcr 83% 23.9% focal therapy vs. 79% 24.8% rp, respectively. similar results demonstrated cohort-based analysis follow-up six years . use different definitions oncological failure two arms another limitation studies. recurrence rp seen failure, second hifu permitted focal group. current data hifu evaluation assessment treatment (heat) registry indicates repeat-hifu significantly decrease urinary erectile function . however, change failure definition re-evaluated. important note, results achieved centres dedicated focal program patients mpmri targeted systematic biopsies full template mapping biopsies. prospective heat registry analysed 800 men undergoing focal hifu localised pca . functional data indicate low treatment-related toxicity less 4% decrease pad-free incontinence reduction iief 0.4 points. impact salvage therapies focal therapy investigated small series . salvage rp necessary, reported functional oncological outcomes comparable treatment-naive patients . one comparative rct conducted very-low risk population, currently strong movement away form active treatment. study comparing padeliporfin-based vascular targeted pdt vs. found median follow-up 24 months less patients progressed pdt arm compared arm (adjusted hr: 0.34, 95% ci: 0.24–0.46), needed less radical therapy (6% vs. 29%, p < 0.0001). updated results published 2018 showing benefits maintained four years . nevertheless, limitations study include unusually high observed rate disease progression arm (58% two years) patients arm chose undergo radical therapy without clinical indication may introduced confounding bias. finally, arm undergo confirmatory biopsy mri scanning, representative contemporary practice. matched-pair analysis comparing focal cryo therapy 76% isup grade group 1 cancers failed demonstrate significant advantages mfs os . available evidence indicates focal therapy associated less aes whole gland radical treatments. many patients included trials would currently considered treated. robust prospective trials reporting standardised 15-year oncological outcomes needed patients clinically significant cancers unrestricted recommendations support focal therapy routine clinical practice made . currently, focal therapy using hifu cryotherapy performed within context prospective registry. ablative modalities treatment strategies offered well-designed prospective trial setting. order allow quality analysis collected data, prospective registry adhere ema recommendations (guideline registry-based studies ema/426390/2021), emphasises need clear follow-up timelines timely recording, completeness core data consecutive patients enrolled, analysis plan defined intervals data quality management. near future eau offer quality registry within pioneer network.